Current Pharmaceutical Product “Pipeline” for AD Treatment

Currently there are numerous medicines under investigation in the pharmaceutical pipeline. Both the European Agency for the Evaluation of Medicinal Products (EMEA) and the US Food and Drug Administration (FDA) were reviewed to determine the current pipeline. Table 3 indicated the new medications under development for AD.

Table 8:. New Medicines in Development for Alzheimer disease[i]^, [ii]

Drug name	Indication	Company	Development Status
271046 (5HT6 antagonist)	Alzheimer disease	GlaxoSmithKline	Phase 1
737552 (s-8510) [iii]	Alzheimer disease	GlaxoSmithKline	Phase II
Abilify (aripipazole)	Alzheimer disease	Bristol-Myers Squibb	Phase III
Alzhemed	Alzheimer disease	Neurochem	Phase III
Ampalex (CX 516)	Alzheimer disease, mild cognitive impairment	Cortex Pharmaceuticals	Phase II
Apan-1, APAN	Alzheimer disease	Praecis Pharmaceutical	Phase I
Breaker peptide	Alzheimer disease	Serono	Phase I
CPI-1189	Alzheimer disease	Centaur Pharmaceutcals	Phase II
DP 543	Alzheimer disease	Bristol-Myers Squibb	Phase II
MEM 1003	Alzheimer disease, mild cognitive impairment, vascular dementia	Memory Pharmaceuticals	Phase I
MKC 2313	Alzheimer disease	Mitsubishi Pharma	Phase II
MPC 7869	Alzheimer disease	Mzriad Genetics	Phase II
Namenda	Alzheimer disease, neuropathic pain	Forest Laboratories	Phase III
Nerve growth factor (gene therapy)	Alzheimer disease	Ceregene	Phase I
NS 2330	Alzheimer disease, Parkinson disease	Boehringer-Ingelheim Pharmaceuticals	Phase II
Phenserine tartate	Alzheimer disease	Axonyx	Phase II/III
SR 57667	Alzheimer disease, Parkinson’s disease	Sanofi-Synthelabo	Phase II
SR 57746	Alzheimer disease, antimitotic neuropathies (AIM), multiple sclerosis	Sanofi-Synthelabo	Phase II

---

[i] http://www.phrma.org/newmedicines/newmedsdb/drugs.cfm.  Pharmaceutical Research and Manufacturers of America.  Last accessed March 09, 2004.

[ii] http://www.emea.eu.int European Agency for the Evaluation of Medicinal Products. Last accesses March 09, 2004.

[iii] Abe K, Takayama C, Zoshimura K. Effects of S- 8510, a novel benzodiazepine receptor partial inverse agonist, on basal forebrain lesioning-induced dysfunction in rats. Eur J Pharmacol. 1998 ; 347 (2-3) : 145-52.